Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, California, December 6-9, 2014, highlighting the following:
•An oral presentation of phase 3 AETHERA clinical trial results for ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at risk of relapse;
Help employers find you! Check out all the jobs and post your resume.
